LFB Group
http://www.lfb.fr/en/home.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LFB Group
Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic
The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.
Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- GTC Biotherapeutics, Inc.
- LFB Biotechnologies, S.A.S.
- rEVO Biologics